EP Patent

EP1625849A1 — Pharmaceutical composition comprising drospirenone and ethynylestradiol

Assigned to Laboratorios Liconsa SA · Expires 2006-02-15 · 20y expired

What this patent protects

A pharmaceutical composition that comprises drospirenone and ethynylestradiol with an improved dissolution rate. A method of preparation of a pharmaceutical formulation that comprises drospirenone and ethynylestradiol in order to improve its dissolution profile. Said formul…

USPTO Abstract

A pharmaceutical composition that comprises drospirenone and ethynylestradiol with an improved dissolution rate. A method of preparation of a pharmaceutical formulation that comprises drospirenone and ethynylestradiol in order to improve its dissolution profile. Said formulation can be used to produce an anovulatory effect when administered correctly in humans.

Drugs covered by this patent

Patent Metadata

Patent number
EP1625849A1
Jurisdiction
EP
Classification
—
Expires
2006-02-15
Drug substance claim
No
Drug product claim
No
Assignee
Laboratorios Liconsa SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.